Agios Pharmaceuticals

Cambridge has a habit of producing companies that sound academic right up until the money starts moving, the science starts landing, and patients start showing up in the data. Agios Pharmaceuticals did not begin as a brand exercise. It began in 2008 as a hard scientific question posed by Lewis C. Cantley, Ph.D., Tak W. Mak, Ph.D., and Craig B. Thompson, M.D., 3 scientists staring at cellular metabolism and asking why cancer and blood disorders behave like fuel addicts. ARCH Venture Partners and Flagship Ventures funded the idea early, not because it was fashionable, but because it was defensible.

By 2013, that thesis had enough spine to go public at $18/share, jumping nearly 74% on day 1. What followed was not linear growth but learned restraint. Agios figured out when ownership mattered and when liquidity mattered more. In 2021, it sold its oncology business to Servier for ~$1.8B in cash at closing, plus milestones and royalties. In 2024, it monetized vorasidenib royalties to Royalty Pharma for $905M and pulled in a $200M Servier milestone. This is not deal-chasing behavior. This is balance sheet choreography, the kind that rarely gets discussed in startup news but quietly determines who survives the next decade.

Today, Agios is a rare disease company with metabolism as its engine and hematology as its lane. Brian Goff, CEO and board member, brings 30+ years of rare disease commercial experience to a portfolio built for durability. Cecilia Jones, CFO, runs the capital stack with discipline. Sarah Gheuens, M.D., Ph.D., CMO and Head of R&D, pushes the science forward. Tsveta Milanova, CCO, carries the commercial execution. This is not a vanity roster. It is an operating unit designed to convert approvals into franchises.

The backbone is PYRUKYND, a first-in-class oral activator of pyruvate kinase that treats the disease mechanism, not the symptoms. Approved in the U.S., EU, and Great Britain for PK deficiency, it is now advancing into larger moments. A thalassemia sNDA filed in 12/2024 with a 9/7/2025 PDUFA date. A Phase 3 sickle cell program progressing. Pediatric PK deficiency in Phase 3. Tebapivat, also known as AG-946, extending the platform. AG-181 targeting PKU. AG-236, an siRNA targeting TMPRSS6, IND-cleared in 2025. One metabolic thesis, multiple shots on goal, all within reach.

The financial swing tells the story cleanly. A $352.1M net loss in 2023 flips to $673.7M in net income in 2024, driven by non-dilutive strategy, not accounting tricks. PYRUKYND sales jumped 45% YoY in Q2 2025 as thalassemia approval approaches. This is the kind of operating leverage that rarely trends on social feeds but consistently reshapes startup news cycles when approvals hit.

Agios is hiring, building, and widening its metabolic lane with intent. Follow if you track disciplined biotech. Reach out if you understand platform science. Apply if you want to work where biology, capital, and restraint move in the same direction. This is not noise. This is momentum that compounds.